Scottish medtech Altair has raised £2.25 million in pre-Series A funding, which will enable the company to continue the development of its wearable respiratory sensor and real-time monitoring technology.

Altair’s product uses AI to identify a range of adverse respiratory events and issue alerts on them, with the aim of preventing avoidable early deaths. The wearable sensor, currently in development, will be one of the smallest biosensors on the market and works by transmitting data to a cloud platform via a smartphone or data hub.

If adverse changes are detected, the platform can alert the user, doctors or nurses, emergency services or the patient’s household members. It is thought that the technology will be capable of monitoring large numbers of patients within any location at the same time.

Demonstrating investor confidence in Altair’s product, the company’s initial funding target has been well oversubscribed. The funding will contribute to validating the technology ahead of the company lodging an application to receive Class 2 Medical Device clearance.

Dr Bruce Henderson, CEO of Altair, commented: “From my work as a forensic medical examiner I witnessed a large number of preventable deaths from patients with respiratory conditions. This inspired me to build up a team of specialists to develop the technology, which is now undergoing clinical trials in a range of respiratory conditions.”

“We see huge potential for our device across a wide range of patients. We are delighted to have secured the backing of a syndicate of investors, which allows us to further prove the device and launch it in the UK, US and other countries in the near future.”

Contact us


Tel: +44 (0)1424 777745

Fax: +44 (0)1424 777746



Kirkham Young Ltd.
The Old Court House
North Trade Road
East Sussex
TN33 0EX